Table 2. Association of HLA-G 3′UTR polymorphisms with gender and clinicopathological characteristics of pediatric HL patients.
| GENDER | Femalen= 45 (%) | Malen= 68 (%) | OR(95% CI) | P | |
|---|---|---|---|---|---|
| +3187A/G | |||||
| A | 53 (59) | 101 (74) | 1.00 | 0.016 | |
| G | 37 (41) | 35 (26) | 0.49 (0.28-0.89) | ||
| AA | 15 (33.3) | 38 (55.9) | 1.00 | 0.018 | |
| AG+GG | 30 (66.7) | 30 (44.1) | 0.39 (0.18-0.86) | ||
| Treatment outcome (tumor relapse) | Event (No) | Event (Yes) | OR(95% CI) | P | |
| +3010C/G | |||||
| C | 91 (51) | 30 (68) | 1.00 | 0.027 | |
| G | 89 (49) | 14 (32) | 0.45 (0.21-0.94) | ||
| CC+CG | 69 (76.7) | 21 (95.5) | 1.00 | 0.025 | |
| GG | 21 (23.3) | 1 (4.5) | 0.16 (0.02-1.23) | ||
| +3027C/A | |||||
| C | 170 (94) | 37 (84) | 1.00 | 0.026 | |
| A | 10 (6) | 7 (16) | 3.13 (0.10-8.94) | ||
| CC | 82 (91.1) | 15 (68.2) | 1.00 | 0.010 | |
| AA+CA | 8 (8.9) | 7 (31.8) | 4.78 (1.51 −15.17) | ||
| +3142C/G | |||||
| C | 92 (51) | 30 (68) | 1.00 | 0.031 | |
| G | 88 (49) | 14 (32) | 0.45 (0.21-0.95) | ||
| GG+CG | 70 (77.8) | 21 (95.5) | 1.00 | 0.032 | |
| CC | 20 (22.2) | 1 (4.5) | 0.17 (0.02 −1.32) | ||
| Ann Arbor Stages | Stage I | Stage II | Stage III | Stage IV | P* |
| +3196C/G | |||||
| C | 8 (66.7) | 72 (66.7) | 28 (63.6) | 52 (83.9) | 0.033 |
| G | 4 (33.3) | 36 (33.3) | 16 (36.4) | 10 (16.1) | |
| CC | 2 (33.3) | 24 (44.4) | 10 (45.5) | 20 (66.7) | 0.021 |
| CG+GG | 4 (66.7) | 30 (55.6) | 12 (44.5) | 10 (33.3) | |
OR=odds ratio; 95%CI=95% confidence interval.
P* chi-square test for trend.
CTRL: controls of individuals without hematological malignancies.